Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial

Kassoum Kayentao, Ogobara K Doumbo, Louis K Pénali, André T Offianan, Kirana M Bhatt, Joshua Kimani, Antoinette K Tshefu, Jack H T Kokolomami, Michael Ramharter, Pablo Martinez de Salazar, Alfred B Tiono, Alphonse Ouédraogo, Maria Dorina G Bustos, Frederick Quicho, Isabelle Borghini-Fuhrer, Stephan Duparc, Chang-Sik Shin, Lawrence Fleckenstein, Kassoum Kayentao, Ogobara K Doumbo, Louis K Pénali, André T Offianan, Kirana M Bhatt, Joshua Kimani, Antoinette K Tshefu, Jack H T Kokolomami, Michael Ramharter, Pablo Martinez de Salazar, Alfred B Tiono, Alphonse Ouédraogo, Maria Dorina G Bustos, Frederick Quicho, Isabelle Borghini-Fuhrer, Stephan Duparc, Chang-Sik Shin, Lawrence Fleckenstein

Abstract

Background: Children are most vulnerable to malaria. A pyronaridine-artesunate pediatric granule formulation is being developed for the treatment of uncomplicated Plasmodium falciparum malaria.

Methods: This phase III, multi-center, comparative, open-label, parallel-group, controlled clinical trial included patients aged ≤12 years, bodyweight ≥5 to <25 kg, with a reported history of fever at inclusion or in the previous 24 h and microscopically-confirmed uncomplicated P. falciparum malaria. Patients were randomized (2:1) to pyronaridine-artesunate granules (60/20 mg) once daily or artemether-lumefantrine crushed tablets (20/120 mg) twice daily, both dosed by bodyweight, orally (liquid suspension) for three days.

Results: Of 535 patients randomized, 355 received pyronaridine-artesunate and 180 received artemether-lumefantrine. Day-28 adequate clinical and parasitological response (ACPR), corrected for re-infection using polymerase chain reaction (PCR) genotyping (per-protocol population) was 97.1% (329/339; 95% CI 94.6, 98.6) for pyronaridine-artesunate; 98.8% (165/167; 95% CI 95.7, 99.9) for artemether-lumefantrine. The primary endpoint was achieved: pyronaridine-artesunate PCR-corrected day-28 ACPR was statistically significantly >90% (P < .0001). Pyronaridine-artesunate was non-inferior to artemether-lumefantrine: treatment difference -1.8% (95% CI -4.3 to 1.6). The incidence of drug-related adverse events was 37.2% (132/355) with pyronaridine-artesunate, 44.4% (80/180) with artemether-lumefantrine. Clinical biochemistry results showed similar mean changes versus baseline in the two treatment groups. From day 3 until study completion, one patient in each treatment group had peak alanine aminotransferase (ALT) >3 times the upper limit of normal (ULN) and peak total bilirubin >2xULN (i.e. within the Hy's law definition).

Conclusions: The pyronaridine-artesunate pediatric granule formulation was efficacious and was non-inferior to artemether-lumefantrine. The adverse event profile was similar for the two comparators. Pyronaridine-artesunate should be considered for inclusion in paediatric malaria treatment programmes.

Trial registration: ClinicalTrials.gov: identifier NCT00541385.

Figures

Figure 1
Figure 1
Study design and patient flow.
Figure 2
Figure 2
Kaplan–Meier analysis (intent-to-treat population) showed no difference between pyronaridine-artesunate granules and artemether-lumefantrine crushed tablets for (a) recrudescence rate (P = .53, log-rank test) or (b) re-infection rate (P = .77, log-rank test).
Figure 3
Figure 3
Kaplan–Meier analysis (intent-to-treat population) showed significantly faster (a) parasite clearance time (P = .02, log-rank test) and (b) fever clearance time (P = .049, log-rank test) with pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets.

References

    1. Roll Back Malaria Partnership Secretariat. World malaria Day 2010. Africa Update. .
    1. World Health Organization. World malaria report 2011. .
    1. World Health Organization. Guidelines for the treatment of malaria. second. .
    1. World Health Organization. WHO list of prequalified medicinal products. .
    1. Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SS, Bustos DG, Tjitra E, Bedu-Addo G, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet. 2010;375:1457–1467. doi: 10.1016/S0140-6736(10)60322-4.
    1. Rueangweerayut R, Phyo A, Uthaisin C, Poravuth Y, Binh T, Tinto H, Pénali L, Valecha N, Tien N, Abdulla S, Borghini-Fuhrer I, Duparc S, Shin C-S, Fleckenstein L. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. NEJM. 2012;366:1298–1309. doi: 10.1056/NEJMoa1007125.
    1. Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phyo A, Valecha N, Rao BH, Tjitra E, Purnama A, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L. Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomised, double-blind, non-inferiority trial. PLoS One. 2011;6:e14501. doi: 10.1371/journal.pone.0014501.
    1. Holding PA, Snow RW. Impact of Plasmodium falciparum malaria on performance and learning: review of the evidence. Am J Trop Med Hyg. 2001;64:68–75.
    1. Idro R, Marsh K, John CC, Newton CR. Cerebral malaria; mechanisms of brain injury and strategies for improved neuro-cognitive outcome. Pediatr Res. 2010;64:267–274.
    1. Kihara M, de Haan M, Garrashi HH, Neville BG, Newton CR. Atypical brain response to novelty in rural African children with a history of severe falciparum malaria. J Neurol Sci. 2010;296:88–95. doi: 10.1016/j.jns.2010.05.018.
    1. Ramharter M, Kurth F, Schreier AC, Nemeth J, Glasenapp I, Belard S, Schlie M, Kammer J, Koumba PK, Cisse B, Mordmuller B, Lell B, Issifou S, Oeuvray C, Fleckenstein L, Kremsner PG. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis. 2008;198:911–919. doi: 10.1086/591096.
    1. World Health Organization. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria (WHO/HTM/RBM/2003.50) .
    1. Severe falciparum malaria World Health Organization. Communicable Diseases Cluster. Trans R Soc Trop Med Hyg. 2000;94(Suppl 1):S1–S90.
    1. Felger I, Beck HP. Genotyping of Plasmodium falciparum. PCR-RFLP analysis. Meth Mol Med. 2002;72:117–129.
    1. Medicines for Malaria Venture, World Health Organization. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. .
    1. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) Guidance for industry drug-induced liver injury: premarketing clinical evaluation. .
    1. Martensson A, Stromberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, Olliaro P, Ali AS, Bjorkman A. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis. 2005;41:1079–1086. doi: 10.1086/444460.
    1. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet. 2007;369:757–765. doi: 10.1016/S0140-6736(07)60160-3.
    1. Suputtamongkol Y, Newton PN, Angus B, Teja-Isavadharm P, Keeratithakul D, Rasameesoraj M, Pukrittayakamee S, White NJ. A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria. Br J Clin Pharmacol. 2001;52:655–661.
    1. Ringwald P, Bickii J, Basco LK. Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children. Clin Infect Dis. 1998;26:946–953. doi: 10.1086/513942.
    1. Ringwald P, Bickii J, Basco L. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet. 1996;347:24–28. doi: 10.1016/S0140-6736(96)91558-5.
    1. Looareesuwan S, Kyle DE, Viravan C, Vanijanonta S, Wilairatana P, Wernsdorfer WH. Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. Am J Trop Med Hyg. 1996;54:205–209.
    1. Price R, van Vugt M, Phaipun L, Luxemburger C, Simpson J, McGready R, ter Kuile F, Kham A, Chongsuphajaisiddhi T, White NJ, Nosten F. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg. 1999;60:547–555.
    1. Kurth F, Belard S, Adegnika AA, Gaye O, Kremsner PG, Ramharter M. Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. Lancet Infect Dis. 2010;10:125–132. doi: 10.1016/S1473-3099(09)70327-5.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir